With three deals over as many weeks, France’s Ipsen SA has rapidly beefed up its access to external innovation in its targeted therapeutic areas of oncology/hematology, rare diseases and neurology, with the latest agreement being an exclusive option on two discovery programs at Chicago-based Exicure, Inc., in two rare neurodegenerative diseases, Huntington’s disease and Angelman syndrome.
The Paris-headquartered mid-sized pharmaceutical company has signaled its interest in restocking its early R&D pipeline under CEO David Loew, a business strategy that also includes cost controls and a focus on specialty products
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
